Hepatitis B surface antigen levels at 6 months after treatment can predict the efficacy of lamivudine-adefovir combination therapy in patients with lamivudine-resistant chronic hepatitis B

BACKGROUND/AIMS: Quantitation of hepatitis B surface antigen (HBsAg) is an increasingly popular method to determine the treatment response in chronic hepatitis B (CHB) patients. The clinical value of HBsAg level measurement during rescue therapy for lamivudine (LMV)-resistant CHB patients have not b...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Jeong Han, Moon, Hee Won, Ko, Soon Young, Choe, Won Hyeok, Kwon, So Young
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Association for the Study of the Liver 2014
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4197176/
https://www.ncbi.nlm.nih.gov/pubmed/25320731
http://dx.doi.org/10.3350/cmh.2014.20.3.274

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4197176/
https://www.ncbi.nlm.nih.gov/pubmed/25320731
http://dx.doi.org/10.3350/cmh.2014.20.3.274

Ejemplares similares